{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:43:59Z","timestamp":1788536639464,"version":"build-2803163510"},"reference-count":22,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2024,6,3]]},"DOI":"10.18632\/oncotarget.28589","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:42:33Z","timestamp":1717418553000},"page":"355-359","source":"Crossref","is-referenced-by-count":11,"title":["Bruton\u2019s tyrosine kinase inhibitor-related cardiotoxicity: The quest for predictive biomarkers and improved risk stratification"],"prefix":"10.18632","volume":"15","author":[{"given":"Jai N.","family":"Patel","sequence":"first","affiliation":[{"name":"Department of Cancer Pharmacology and Pharmacogenomics, Atrium Health Levine Cancer Institute, Charlotte, NC 28204, USA"},{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai","family":"Singh","sequence":"additional","affiliation":[{"name":"Sanger Heart and Vascular Institute, Atrium Health, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA"},{"name":"Department of Hematologic Malignancies and Blood Disorders, Atrium Health Levine Cancer Institute, Charlotte, NC 28204, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"37","author":"Devereux","year":"2015","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"publisher","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"10","author":"Goy","year":"2018","journal-title":"Haematologica"},{"key":"3","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis","volume":"1","author":"Pinto","year":"2019","journal-title":"PLoS One"},{"key":"4","article-title":"Cardiovascular Adverse Effects of Novel Bruton Tyrosine Kinase Inhibitors: What All Cardiologists Should Know","author":"Copeland-Halperin","year":"2023","journal-title":"Am Coll Cardiol"},{"key":"5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.25259\/IJMIO_1_2022","article-title":"Ibrutinib and atrial fibrillation as cardiotoxicity - A new safety warning that impacts overall survival","volume":"7","author":"Gopal","year":"2022","journal-title":"Int J Mol Immuno Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","article-title":"Ibrutinib-Associated Atrial Fibrillation","volume":"4","author":"Nohria","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"7","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-16-0463","article-title":"The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia","volume":"2","author":"Byrd","year":"2017","journal-title":"Clin Cancer Res"},{"key":"8","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase","volume":"14","author":"Lundby","year":"2020","journal-title":"Circulation"},{"key":"9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-137800","article-title":"Evaluation of the Incidence and Risk Factors Associated with Major Cardiovascular Events in Patients Receiving Acalabrutinib Therapy","volume":"13","author":"Bhat","year":"2020","journal-title":"Blood"},{"key":"10","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Christian","year":"2017","journal-title":"Blood Adv"},{"key":"11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk factors for the development of atrial fibrillation on ibrutinib treatment","volume":"6","author":"Akhter","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"12","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"5","author":"Chanan-Khan","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"13","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/hon.3126","article-title":"Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study","volume":"4","author":"Reda","year":"2023","journal-title":"Hematol Oncol"},{"key":"14","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1200\/JCO.22.00255","article-title":"A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts","volume":"4","author":"Rup\u00e9rez","year":"2023","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-23-0421","article-title":"Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia","volume":"2","author":"Ghosh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cdtm.2019.12.005","article-title":"The era of clinical application of gene diagnosis in cardiovascular diseases is coming","volume":"5","author":"Song","year":"2019","journal-title":"Chronic Dis Transl Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s11886-023-01906-6","article-title":"Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism","volume":"2","author":"Song","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"18","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1182\/bloodadvances.2022007938","article-title":"International consensus statement on the management of cardiovascular risk of Bruton\u2019s tyrosine kinase inhibitors in CLL","volume":"6","author":"Ysebaert","year":"2022","journal-title":"Blood Adv"},{"key":"19","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement From the American Heart Association","volume":"14","author":"Olshansky","year":"2021","journal-title":"Circulation"},{"key":"20","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive Cardiotoxicity: The Clinical Crucible of Cardio-Oncology","volume":"4","author":"Okwuosa","year":"2022","journal-title":"JACC CardioOncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"e000067","DOI":"10.1161\/HCG.0000000000000067","article-title":"Genetic Testing for Inherited Cardiovascular Diseases: A Scientific Statement From the American Heart Association","volume":"1","author":"Sturm","year":"2020","journal-title":"Circ Genom Precis Med"},{"key":"22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jaccao.2022.12.008","article-title":"Genetic Predisposition to Cardiovascular Disease in Patients With Cancer: A Clinical Perspective","volume":"5","author":"Filippatos","year":"2023","journal-title":"JACC CardioOncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:43:19Z","timestamp":1717418599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,6,3]]}},"alternative-id":["28589"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28589","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}